Parkinson DiseaseMPPNNCT05065151
Understanding Motivation in Parkinson's Patients Through Neurophysiology
A study testing Stimulation on, Stimulation off and Decision Making Task in people with Parkinson Disease and Deep Brain Stimulation, run by University of California, San Francisco at 1 site in United States.
Trial summary
The study aims to better understand motivation and value-based decision-making in Parkinson's patients through neurophysiology using Medtronic's Percept DBS device. By combining behavioral tasks with neural recordings, the study seeks to uncover how DBS affects motivation, particularly in relation to effort, reward… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parkinson Disease, Deep Brain Stimulation, Motivation
- What is being tested?
- Stimulation on, Stimulation off and Decision Making Task
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Oct 2021to 1 Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Has Parkinson's Disease or Dystonia
- Has Medtronic Percept or RC+S DBS device implanted in either GPI or STN
- Has DBS device implanted either bilaterally or unilaterally
- Male or female
- More than 1 month post-DBS surgery
Who cannot join
- Severe cognitive impairments
- Has MOCA score below 20
- Pregnancy
- Age less than 18 years old
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of California San Francisco
San Francisco, California, 94158
Sarah Wang, PhD, 415-353-7885, Sarah.Wang@ucsf.edu
Simon J Little, MBBS, PhD
About this study
The study aims to better understand motivation and value-based decision-making in Parkinson's patients through neurophysiology using Medtronic's Percept DBS device. By combining behavioral tasks with neural recordings, the study seeks to uncover how DBS affects motivation, particularly in relation to effort, reward, and timing.
Read the detailed description
Participants will perform reward-based decision-making tasks designed to assess both self-benefitting and prosocial motivation. The tasks will evaluate how effort and reward influence decision-making, as well as how proximity to a deadline impacts choices. These tasks will be conducted in both clinic and home settings.
Throughout the study, participants will remain on their regular dopaminergic medications. Each participant will complete sessions under two stimulation conditions: their usual DBS settings and with DBS turned off. Neural activity will be recorded using the Percept device, which enables real-time and chronic at-home data streaming. Additionally, participants will wear a device that captures movement, sleep, heart rate variability, and self-reported measures.
The primary outcomes are behavioral: changes in reaction time, acceptance rate, and success rate across different DBS conditions. The secondary outcomes focus on identifying neural oscillatory biomarkers time-locked to specific decision-making events. By linking brain activity to motivational behavior, this study aims to advance our understanding of non-motor symptoms in PD and inform the development of adaptive DBS algorithms targeting these symptoms.
- Conditions
- Parkinson Disease, Deep Brain Stimulation, Motivation
- Being tested
- Stimulation on, Stimulation off, Decision Making Task
- Keywords
- Parkinson's, Medtronic, Percept, DBS, Deep Brain Stimulation, Parkinson's Disease, Parkinson Disease, PD, Reward-based decision making, Task
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stimulation onOther
Also called Medtronic Percept
Stimulation from Percept DBS will be on while the patient is playing a decision-making game on a computer-based application.
Stimulation offOther
Also called Medtronic Percept
Stimulation from Percept DBS will be off while the patient is playing a decision-making game on a computer-based application.
Decision Making TaskBehavioural
Patients will be playing a decision making task through a computer-based application.
| Study group | Role | What they receive |
|---|---|---|
| Stimulation | Experimental | Patients will be getting standard clinically acceptable stimulation within already safety validated stimulation ranges through their Medtronic Percept device. Receives: Other: Stimulation on; Behavioral: Decision Making Task |
| No Stimulation | Experimental | Patients will have stimulation turned off through their Medtronic Percept device. Receives: Other: Stimulation off; Behavioral: Decision Making Task |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent of Risky Decisions made with Percept DBS stimulation on for Parkinson's Disease Patients
Patients' responses on the tablet will be recorded in-clinic and at home. The investigators will tally their choices from the value-based decision making game (risky versus safe decisions) and report an average of risky responses.
Measured: The values will be collected starting from admission in clinic and the at-home paradigm. Data collection and analysis of said values can take up to three years
Percent of Risky Decisions made with Percept DBS stimulation off for Parkinson's Disease Patients
Patients' responses on the tablet will be recorded in-clinic and at home. The investigators will tally their choices from the value-based decision making game (risky versus safe decisions) and report an average of risky responses.
Measured: The values will be collected starting from admission in clinic and the at-home paradigm. Data collection and analysis of said values can take up to three years
Reaction Time During Decision-Making Task
The investigators will measure the time it takes for patients to make each decision on the value-based decision-making task in the clinic.
Measured: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Task Success Rate
The investigators will calculate the percentage of trials in which patients complete the task successfully according to predefined task performance criteria.
Measured: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Acceptance Rate of Risky Versus Safe Options
The proportion of trials where patients accept risky versus safe options will be calculated and compared across stimulation ON and OFF conditions.
Measured: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Force Exertion During Motor Responses
Force data will be recorded during motor responses to evaluate physical engagement and motor control during task performance.
Measured: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Low frequency local field potentials
Local field potentials (LFPs) will be recorded from the implanted Percept device to evaluate neural activity during decision making under different stimulation conditions. Low frequency power will be calculated during specific time intervals during the task. Cardiac artifact will be removed with electrocardiogram (ECG) measurements recorded during the same task.
Measured: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Electroencephalogram (EEG) theta band power
Scalp EEG will be recorded concurrently with task performance to assess cortical activity patterns during decision-making. Average theta band power will be calculated in specific time intervals during the task.
Measured: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Electroencephalogram (EEG) beta band power
Scalp EEG will be recorded concurrently with task performance to assess cortical activity patterns during decision-making. Average beta band power will be calculated in specific time intervals during the task.
Measured: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Electroencephalogram (EEG) gamma band power
Scalp EEG will be recorded concurrently with task performance to assess cortical activity patterns during decision-making. Average gamma band power will be calculated in specific time intervals during the task.
Measured: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Electroencephalogram (EEG) alpha band power
Scalp EEG will be recorded concurrently with task performance to assess cortical activity patterns during decision-making. Average alpha band power will be calculated in specific time intervals during the task.
Measured: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Secondary outcomes (6)
Interaction Between Neural Low Frequency Power in the LFP with Reaction Time (seconds)
We will assess the effect of reaction time on low frequency power in the LFP data (theta, alpha, beta power) recorded from the Percept device with statistical modeling.
Measured: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Interaction Between Neural Low Frequency Power in the LFP with Success Rate (percentage)
We will assess the effect of success rate on low frequency power in the LFP data (theta, alpha, beta power) recorded from the Percept device with statistical modeling.
Measured: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Interaction Between Neural Low Frequency Power in the LFP with Force Exerted (arbitrary units)
We will assess the effect of force exerted on low frequency power in the LFP data (theta, alpha, beta power) recorded from the Percept device with statistical modeling.
Measured: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Interaction Between Neural Low Frequency Power in the EEG with Reaction Time (seconds)
We will assess the effect of reaction time on low frequency power in the EEG data (theta, alpha, beta power) recorded from the Percept device with statistical modeling.
Measured: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Interaction Between Neural Low Frequency Power in the EEG with Success Rate (percentage)
We will assess the effect of success rate on low frequency power in the EEG data (theta, alpha, beta power) recorded from the Percept device with statistical modeling.
Measured: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Interaction Between Neural Low Frequency Power in the EEG with Force Exerted (arbitrary units)
We will assess the effect of force exerted on low frequency power in the EEG data (theta, alpha, beta power) recorded from the Percept device with statistical modeling.
Measured: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2021
- Study start30 Oct 2021
- Primary completion1 Dec 2030 (estimated)
- Study completion1 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Model description
- Within subject crossover counterbalanced study.
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Collaborators
- Yale University, Rune Labs, University of Birmingham
- Responsible party
- Sponsor
- Investigators
- Simon J Little, MBBS, PhD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05065151
- Sponsor's protocol ID
- 20-31239
- Acronym
- MPPN
- Status last verified
- Jun 2026
- First submitted
- 17 Sep 2021
- Last updated
- 5 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Future data sharing will be covered by UCSF data sharing compliance rules.
Publications
Rutledge RB, Skandali N, Dayan P, Dolan RJ. A computational and neural model of momentary subjective well-being. Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12252-7. doi: 10.1073/pnas.1407535111. Epub 2014 Aug 4.
PubMed 25092308Rutledge RB, Skandali N, Dayan P, Dolan RJ. Dopaminergic Modulation of Decision Making and Subjective Well-Being. J Neurosci. 2015 Jul 8;35(27):9811-22. doi: 10.1523/JNEUROSCI.0702-15.2015.
PubMed 26156984Eldar E, Rutledge RB, Dolan RJ, Niv Y. Mood as Representation of Momentum. Trends Cogn Sci. 2016 Jan;20(1):15-24. doi: 10.1016/j.tics.2015.07.010. Epub 2015 Nov 3.
PubMed 26545853Blain B, Rutledge RB. Momentary subjective well-being depends on learning and not reward. Elife. 2020 Nov 17;9:e57977. doi: 10.7554/eLife.57977.
PubMed 33200989Talbot J, Cutler J, Tamm M, Little SJ, Harmer CJ, Husain M, Lockwood PL, Apps MAJ. Dopamine Boosts Motivation for Prosocial Effort in Parkinson's Disease. J Neurosci. 2026 Feb 25;46(8):e1593242024. doi: 10.1523/JNEUROSCI.1593-24.2024.
PubMed 39746820Pisauro MA, Pollicino D, Fisher L, Apps MAJ. Neural and computational mechanisms of effort under the pressure of a deadline. Nat Commun. 2026 Jul 28;17(1):9169. doi: 10.1038/s41467-026-75987-6.
PubMed 42660916
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Understanding Motivation in Parkinson's Patients Through Neurophysiology
- ClinicalTrials.gov ID
- NCT05065151
- Acronym / sponsor ID
- MPPN / 20-31239
- Conditions
- Parkinson Disease, Deep Brain Stimulation, Motivation
- Keywords
- Parkinson's, Medtronic, Percept, DBS, Deep Brain Stimulation, Parkinson's Disease, Parkinson Disease, PD
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Collaborators
- Yale University, Rune Labs, University of Birmingham
- Study start
- 30 Oct 2021 (actual)
- Primary completion
- 1 Dec 2030 (estimated)
- Study completion
- 1 Dec 2030 (estimated)
- First posted
- 1 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to better understand motivation and value-based decision-making in Parkinson's patients through neurophysiology using Medtronic's Percept DBS device. By combining behavioral tasks with neural recordings, the study seeks to uncover how DBS affects motivation, particularly in relation to effort, reward, and timing.
Detailed description
Participants will perform reward-based decision-making tasks designed to assess both self-benefitting and prosocial motivation. The tasks will evaluate how effort and reward influence decision-making, as well as how proximity to a deadline impacts choices. These tasks will be conducted in both clinic and home settings.
Throughout the study, participants will remain on their regular dopaminergic medications. Each participant will complete sessions under two stimulation conditions: their usual DBS settings and with DBS turned off. Neural activity will be recorded using the Percept device, which enables real-time and chronic at-home data streaming. Additionally, participants will wear a device that captures movement, sleep, heart rate variability, and self-reported measures.
The primary outcomes are behavioral: changes in reaction time, acceptance rate, and success rate across different DBS conditions. The secondary outcomes focus on identifying neural oscillatory biomarkers time-locked to specific decision-making events. By linking brain activity to motivational behavior, this study aims to advance our understanding of non-motor symptoms in PD and inform the development of adaptive DBS algorithms targeting these symptoms.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Within subject crossover counterbalanced study.
| Arm | Type | Receives |
|---|---|---|
| Stimulation | Experimental | Other: Stimulation on, Behavioral: Decision Making TaskPatients will be getting standard clinically acceptable stimulation within already safety validated stimulation ranges through their Medtronic Percept device. |
| No Stimulation | Experimental | Other: Stimulation off, Behavioral: Decision Making TaskPatients will have stimulation turned off through their Medtronic Percept device. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Has Parkinson's Disease or Dystonia
- Has Medtronic Percept or RC+S DBS device implanted in either GPI or STN
- Has DBS device implanted either bilaterally or unilaterally
- Male or female
- More than 1 month post-DBS surgery
Key exclusion criteria (4 listed)
- Severe cognitive impairments
- Has MOCA score below 20
- Pregnancy
- Age less than 18 years old
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stimulation onAlso: Medtronic PerceptStimulation from Percept DBS will be on while the patient is playing a decision-making game on a computer-based application. | Other | Stimulation |
| Stimulation offAlso: Medtronic PerceptStimulation from Percept DBS will be off while the patient is playing a decision-making game on a computer-based application. | Other | No Stimulation |
| Decision Making TaskPatients will be playing a decision making task through a computer-based application. | Behavioural | No Stimulation, Stimulation |
Primary outcome
Percent of Risky Decisions made with Percept DBS stimulation on for Parkinson's Disease Patients
Time frame: The values will be collected starting from admission in clinic and the at-home paradigm. Data collection and analysis of said values can take up to three years
Patients' responses on the tablet will be recorded in-clinic and at home. The investigators will tally their choices from the value-based decision making game (risky versus safe decisions) and report an average of risky responses.
Percent of Risky Decisions made with Percept DBS stimulation off for Parkinson's Disease Patients
Time frame: The values will be collected starting from admission in clinic and the at-home paradigm. Data collection and analysis of said values can take up to three years
Patients' responses on the tablet will be recorded in-clinic and at home. The investigators will tally their choices from the value-based decision making game (risky versus safe decisions) and report an average of risky responses.
Reaction Time During Decision-Making Task
Time frame: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
The investigators will measure the time it takes for patients to make each decision on the value-based decision-making task in the clinic.
Task Success Rate
Time frame: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
The investigators will calculate the percentage of trials in which patients complete the task successfully according to predefined task performance criteria.
Acceptance Rate of Risky Versus Safe Options
Time frame: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
The proportion of trials where patients accept risky versus safe options will be calculated and compared across stimulation ON and OFF conditions.
Force Exertion During Motor Responses
Time frame: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Force data will be recorded during motor responses to evaluate physical engagement and motor control during task performance.
Low frequency local field potentials
Time frame: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Local field potentials (LFPs) will be recorded from the implanted Percept device to evaluate neural activity during decision making under different stimulation conditions. Low frequency power will be calculated during specific time intervals during the task. Cardiac artifact will be removed with electrocardiogram (ECG) measurements recorded during the same task.
Electroencephalogram (EEG) theta band power
Time frame: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Scalp EEG will be recorded concurrently with task performance to assess cortical activity patterns during decision-making. Average theta band power will be calculated in specific time intervals during the task.
Electroencephalogram (EEG) beta band power
Time frame: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Scalp EEG will be recorded concurrently with task performance to assess cortical activity patterns during decision-making. Average beta band power will be calculated in specific time intervals during the task.
Electroencephalogram (EEG) gamma band power
Time frame: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Scalp EEG will be recorded concurrently with task performance to assess cortical activity patterns during decision-making. Average gamma band power will be calculated in specific time intervals during the task.
Electroencephalogram (EEG) alpha band power
Time frame: The values will be collected starting from admission in clinic. Data collection and analysis of said values can take up to three years.
Scalp EEG will be recorded concurrently with task performance to assess cortical activity patterns during decision-making. Average alpha band power will be calculated in specific time intervals during the task.
6 secondary outcomes
Interaction Between Neural Low Frequency Power in the LFP with Reaction Time (seconds)
Time frame: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Interaction Between Neural Low Frequency Power in the LFP with Success Rate (percentage)
Time frame: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Interaction Between Neural Low Frequency Power in the LFP with Force Exerted (arbitrary units)
Time frame: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Interaction Between Neural Low Frequency Power in the EEG with Reaction Time (seconds)
Time frame: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Interaction Between Neural Low Frequency Power in the EEG with Success Rate (percentage)
Time frame: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Interaction Between Neural Low Frequency Power in the EEG with Force Exerted (arbitrary units)
Time frame: Analysis will occur continuously throughout the study period (up to three years) based on collected behavioral and neural data.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2026.
- Background: PubMed 25092308Rutledge RB, Skandali N, Dayan P, Dolan RJ. A computational and neural model of momentary subjective well-being. Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12252-7. doi: 10.1073/pnas.1407535111. Epub 2014 Aug 4.
- Background: PubMed 26156984Rutledge RB, Skandali N, Dayan P, Dolan RJ. Dopaminergic Modulation of Decision Making and Subjective Well-Being. J Neurosci. 2015 Jul 8;35(27):9811-22. doi: 10.1523/JNEUROSCI.0702-15.2015.
- Background: PubMed 26545853Eldar E, Rutledge RB, Dolan RJ, Niv Y. Mood as Representation of Momentum. Trends Cogn Sci. 2016 Jan;20(1):15-24. doi: 10.1016/j.tics.2015.07.010. Epub 2015 Nov 3.
- Background: PubMed 33200989Blain B, Rutledge RB. Momentary subjective well-being depends on learning and not reward. Elife. 2020 Nov 17;9:e57977. doi: 10.7554/eLife.57977.
- Background: PubMed 39746820Talbot J, Cutler J, Tamm M, Little SJ, Harmer CJ, Husain M, Lockwood PL, Apps MAJ. Dopamine Boosts Motivation for Prosocial Effort in Parkinson's Disease. J Neurosci. 2026 Feb 25;46(8):e1593242024. doi: 10.1523/JNEUROSCI.1593-24.2024.
- Background: PubMed 42660916Pisauro MA, Pollicino D, Fisher L, Apps MAJ. Neural and computational mechanisms of effort under the pressure of a deadline. Nat Commun. 2026 Jul 28;17(1):9169. doi: 10.1038/s41467-026-75987-6.
- Individual participant dataSharing planned: No. Future data sharing will be covered by UCSF data sharing compliance rules.
Related trials for Parkinson Disease
Active, not recruitingPhase 3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Carcinoma, Renal Cell
Not yet recruiting
The Effects of Ischemic Conditioning in Individuals With Parkinson's Disease
Parkinson Disease
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Active, not recruitingPhase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Simon J Little, MBBS, PhD principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Stimulation on, Stimulation off and Decision Making Task in people with Parkinson Disease and Deep Brain Stimulation, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sarah Wang, PhD (415-353-7885, Sarah.Wang@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent of Risky Decisions made with Percept DBS stimulation on for Parkinson's Disease Patients (time frame: The values will be collected starting from admission in clinic and the at-home paradigm. Data collection and analysis of said values can take up to three years). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05065151, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2026; AzTrials last refreshed its copy on 7 Nov 2026.